VIENNA (MedPage Today) -- Metastatic renal cell carcinoma responded about as well to the oral targeted agent pazopanib (Votrient) as to oral sunitinib (Sutent), researchers said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment